Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Herbalife Ltd. (HLF), J.C. Penney Company, Inc. (JCP): Ackman Is Just One Of Many Short Sellers Having a Tough 2013

Recently, Herbalife Ltd. (NYSE:HLF) climbed above $60, meaning that billionaire Bill Ackman’s Pershing Square is finally underwater from its short of the stock last year. The stock has doubled year to date, but had dropped in late 2012 after Ackman had publicly disclosed the short; he began shorting at around $50, and the overall market has returned about 20% since that time. Herbalife Ltd. (NYSE:HLF)- which still has over 40% of the float held short as of the most recent data- is but the highest profile short target which has not only delivered positive returns year to date but in fact outperformed the market.

In fact, Herbalife Ltd. (NYSE:HLF) isn’t even the top performer of stocks with high short interest at the beginning of this year. A better candidate for that honor is SUPERVALU INC. (NYSE:SVU), an owner-operator of grocery stores. SUPERVALU INC. (NYSE:SVU) was trading at $2.50 at the beginning of this year, and rose as high as $8 recently (it currently trades at about $7.40 per share). About 40% of its float had been held short last December. Barry Rosenstein’s JANA Partners has caught some of this move; that fund initiated a position in SUPERVALU INC. (NYSE:SVU) in the first quarter of 2013 (find JANA’s favorite stocks).

Ordinarily, small cap stocks are a good source of alpha for hedge funds and other major investors with the capacity to do in-depth research on individual companies; we’ve found, in fact, that the most popular small cap stocks among hedge funds generate an average excess return of 18 percentage points per year (learn more about our small cap strategy). However, Questcor Pharmaceuticals Inc (NASDAQ:QCOR) and some other small caps have proven to be poor sources of alpha for short sellers. Nearly half of Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s float at the beginning of 2013 was held by short sellers, but after a jump of nearly $15 in one day in late July after a big earnings surprise it is now up about 150% for the year. The pharmaceutical company’s products are designed to treat multiple sclerosis and other medical conditions.

Of course, short sellers have had some victories. Ironically, it’s one of Ackman’s long positions- J.C. Penney Company, Inc. (NYSE:JCP)– which has proven to be one of the better shorts of the year (see Ackman’s stock picks and read our analysis of his recent moves). The department store continues to be unprofitable, and in its most recent quarter revenue fell by 16% compared to the same period in the previous fiscal year.

Bill Ackman in front of Perishi

It’s a challenging environment for brick-and-mortar general retailers as is, and so J.C. Penney Company, Inc. (NYSE:JCP) would have to pull itself back to profitability into the teeth of competition from, Inc. (NASDAQ:AMZN) as well as larger discount retailers such as Wal-Mart Stores, Inc. (NYSE:WMT).

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.